CHEST 2025: INSIDE LOOK
Marriott Marquis, Grand Horizon ABC
Sponsored by an educational grant from Sanofi
Join leading pulmonologists Dr. Antonio Anzueto and Dr. Diego Maselli as they highlight the clinical burden of COPD driven by type 2 inflammation, emphasizing its impact on patient outcomes and unmet needs. They will then review Phase 3 clinical trial data for dupilumab, focusing on its effects across key outcomes, specifically reducing exacerbations, improving lung function, alleviating symptoms, and enhancing quality of life.
Participate in the live Q&A session following the presentations to hear directly from global experts in pulmonology.
This is a non-CME event and does not qualify for CME or CE, or MOC credit. This event is not part of the official CHEST Annual Meeting 2025 conference sessions. This event is not an endorsement by CHEST and does not reflect the views of opinions of CHEST.
Diego Maselli, MD, FCCP
UT Health San Antonio
Professor/Chief
San Antonio, Texas
Antonio Anzueto, MD
South Texas Veterans Healthcare System
Professor
San Antonio, Texas